of these subjects is based only on either microalbuminuria or moderately decreased eGFR (i.e., 30 59 mL/min/1.73 m ),controversy exists -2 about its clinical relevance, 10 17 especially given how little is known about normal kidney function level 18,19 and the epidemiology [ -] [ ] of CKD in the elderly. 20,21 [ ] More information is needed about the prevalence of clinically significant kidney markers such as clinical proteinuria, 22 resistant [ ] hypertension, 23 or anaemia 24 in the older people. 21,26 Data on eGFR change over time is also needed to better define rapid decline in [ -] suggest age attenuates these associations. 35 39 Finally, use of creatinine enzymatic assay and development of new equations improved [ -] eGFR assessment, but while the CKD Epidemiology Collaboration (CKD-EPI) 40 equation has shown to better categorized middle-aged [ ] individuals with respect to long-term outcomes compared with the Modification of Diet in Renal Disease (MDRD) Study equation, 41 [ ] distribution of eGFR values according to one another and risk implications in the oldest are unknown. 42 [ ] We therefore determined age-and sex-specific eGFR using both the MDRD and CKD-EPI equations in community-dwelling people aged 65 years and older participating in the Three-City (3C) cohort study and studied their relations to 6-year all-cause and cardiovascular mortality risks. In a subsample, we also assessed eGFR decline at 4 years and CKD markers.
Subjects and Methods

Study design and participants
The 3C study is a community-based, prospective cohort that included non-institutionalized individuals aged 65 years or older randomly selected from the electoral rolls of Bordeaux, Dijon, and Montpellier ( 8705 participants with baseline serum creatinine and mortality data for 6 years; a subsample of 1298 from Bordeaux was also seen at four years, to assess eGFR decline and CKD markers (Figure 1 ).
Information
Baseline data came from face-to-face interviews and physical examination. Cardiovascular diseases and cardiorenal risk factors were recorded in detail. Open questions about surgery, hospitalization, treatment, and 100 health insurance benefits for severe illness in the % last 2 years provided a history of kidney diseases and nephrectomy. At both baseline and 4 years, medication use was recorded and coded according to the WHO s Anatomical Therapeutical Chemical classification; 44 height and weight were measured and body mass index ' [ ] (BMI) was calculated; seated blood pressure (BP) was measured twice after 5 minutes rest and averaged. Hypertension was defined by a mean systolic BP 140 or diastolic BP 90 mm Hg, 45 or by the use of antihypertensive drugs. Resistant hypertension was defined as a ≥ ≥ [ ] mean systolic BP 140 or diastolic BP 90 mm Hg despite the use of at least three antihypertensive drugs for all participants except those ≥ ≥ with diabetes or CKD as defined below; thresholds for them were 130 or 80 mm Hg. 23 . Diabetes was either self-reported or defined as ≥ [ ] fasting glucose 7 mmol/L or non-fasting 11 mmol/L (in 1 of the participants) or antidiabetic drug treatment. Fasting plasma ≥ ≥ % cholesterol was also measured.
Assessment of kidney function and CKD markers
Serum creatinine was measured with the Jaffe method in a single laboratory at baseline and in a different one at 4 years. In order to standardize creatinine values, 1720 frozen serum samples at baseline and 325 at 4 years were remeasured in a single laboratory with an isotope dilution mass spectrometry (IDMS) traceable enzymatic assay previously shown to provide very reliable eGFR compared to measured GFR. 25 We then developed equations relating the Jaffe and IDMS traceable creatinine and standardized all baseline (1) Six-year mortality was assessed by active follow-up of all participants. It remained unknown for only 8 participants. Causes of death were ascertained by an adjudication committee using all available medical data from hospitals, family physicians or specialists, and proxy interviews as reported earlier Ref [ ] 
Statistical analysis
We compared baseline characteristics between the participants with and without (n 589)creatinine values, with and without the 4-year = follow-up, and with and without CKD risk factors -obesity, BP 160/100, diabetes, history of cardiovascular disease -or self-reported ≥ kidney disease. Subjects without creatinine values were older than those with (76.6 74.2 years), had significantly more versus cardiovascular diseases, but did not differ for other CKD risk factors after adjustment for age (data not shown). We calculated mean, median, interquartile range, and 5 percentile for both MDRD and CKD-EPI eGFR, by sex and 5-year age group, in all participants, and in th those with and without CKD or risk factors. Distribution by eGFR stratum was compared between the two equations. We also provided these values for serum creatinine. Adjusted all-cause and cardiovascular mortality hazard ratios (HR) associated with MDRD-and CKD-EPI-eGFR per 15 mL/min/1.73 m stratum were then estimated in the overall population and by sex with Cox models and eGFR of 2 75 to 89 as the reference category. The 8 participants who were lost to follow-up were excluded. Proportional hazard assumption was checked by examining Cox model residuals. An annual eGFR slope in mL/min/1.73 m /year was calculated for each participant as the 2 difference between baseline and 4-year values divided by exact follow-up time. We used a general linear model to estimate adjusted eGFR slopes (SAS GLM procedure, lsmeans statement with obsmargins option) and 95 confidence intervals, by sex, age, hypertension and % diabetes status, and mean eGFR values. The percentages of participants with eGFR decline rate >4ml/min/1.73m are also shown 2 according to these factors. Ref 3 Finally, we studied the prevalence of each kidney markers according to MDRD-eGFR at 4 years. We 
Results
Baseline characteristics
More than 80 of the participants had at least one CKD risk factor, but fewer than 1 reported kidney disease (Table 1) . They were % % older, more often men, and had lower eGFR with either equation than their counterparts without CKD risk factors or kidney disease (all p-values <0.0001). Baseline eGFRs and BMI were higher in participants with than without the 4-year follow-up (p<0.001); they were also more often women and had less stage 2 hypertension (p<0.05), but other characteristics were similar.
Age-and sex-specific serum creatinine and eGFR values
MDRD eGFRs ranged from 17 to 176 mL/min/1.73 m and CKD-EPI eGFRs from 16 to 109, for serum creatinine values from 32 to 2 322 mol/L ( Table 2 and Supp Table) . Gradient for age was steeper with the CKD-EPI than the MDRD equation. Mean eGFR was higher μ in men than women using either equation, but differences between sexes were attenuated with the CKD-EPI equation. All eGFR values were lower in participants with than without CKD risk factors. The CKD-EPI equation reclassified 117 participants ( with MDRD eGFR 90 were reclassified downward (Table 3) .
≥
Hazard ratios for 6-year mortality related to baseline eGFR
After adjustment for several confounders, only those with an eGFR<45 mL/min/1.73m had significantly higher all-cause mortality 2 than those with an eGFR of 75 to 89, in both men and women and with either equation. (Table 3 ) Cardiovascular mortality significantly exceeded that of the reference group for eGFRs<60 mL/min/1.73 m in the overall population, but for each sex taken separately, it 2 significantly exceeded only for eGFR<45 mL/min/1.73 m .
2
Estimated GFR decline according to participant baseline characteristics and mean eGFR
In the 1298 participants with a 4-year follow-up, the MDRD eGFR decreased in nearly four out of ten by > 2 mL/min/1.73 m /yr, one 2 out of six by > 4, and in 10 by > 5 mL/min/1.73 m /yr. The adjusted mean annual decline was significantly steeper in men than women % 2 and in those with than without diabetes at baseline, but was not related to age and individual mean MDRD eGFR. There was a nonsignificant trend towards steeper decline with increasing blood pressure in those with hypertension. Mean CKD-EPI eGFR decline was 1.53 2.35 mL/min/1.73 m /yr, and was similarly related with studied factors (data not shown). In the sub sample, as MDRD eGFR decreased from 75 to <45 mL/min/1.73 m , the prevalence of microalbuminuria increased from ≥ 2 7.4 to 25.6 , that of microalbuminuria associated with diabetes from 2.8 to 9.8 , clinical proteinuria from 0.6 to 14.0 , resistant % % % % % % hypertension from 3.3 to 15.7 , and of anaemia from 1.5 to 7.5 ( Figure 2 ). Haematuria without leukocyturia did not increase with % % % % decreasing MDRD eGFR.
Prevalence of CKD stages and percentage of kidney damage markers by stage
In the sub sample, the prevalence of CKD using MDRD eGFR was 27.9 ; it was 7.0 for stages 1 2, 16.7 for 3A, and 4.2 for 3B % % -% % or higher. (Figure 3 ) More men than women had CKD stages 1 2, but more women than men had stage 3. Nearly half of both men and women at stages 1 2 had at least one clinically relevant marker and the other half microalbuminuria alone. In men and women with stage -3A, 30 and 16 had markers of kidney damage, and with stage 3B or higher, 64 and 31 , respectively. The prevalence of CKD stages % % % % 1 2 was three times higher in those with than without diabetes, 15.7 5.7 ;it was closer for other stages: 15.1 vs 16.9 for stage 3A, -% vs % % and 5.7 3.9 for stage 3B or higher. Using CKD-EPI, the overall prevalence was also 27.9 ; it was 7. 
Discussion
Knowledge of the specific aspects of CKD epidemiology in the elderly is essential to implement appropriate management. The determination of eGFR distribution for old and very old people, based on IDMS traceable serum creatinine and appropriate equations, is thus an important step forward. This study showed that impaired kidney function was associated with excess mortality with very similar risk estimates using the MDRD or the CKD-EPI equations. Moreover, more than one out of six individuals in this population had fast eGFR decline rate, > 4 mL/min/1.73 m2. The most original findings indicate that only a fraction of those with decreased eGFR have markers of kidney damage and that others than proteinuria should be considered to assess its clinical significance in the elderly.
The large sample size of this population and the low number of participants lost to follow-up (8 out of 8,705 at six years) are major strengths of this study. Other strengths include the use of standardized measures of creatinine over 4 years which reduced systematic bias in the estimate of eGFR decline. This study also has limitations. First, the participation rate was low, and those who participated differed somewhat in age and sex distribution as compared with the general population aged 65 years and over in the three towns. 43 Moreover, the [ ] recruitment procedure led to the selection of urban participants only, who also had a higher socioeconomic levels than the overall French population. Although this might have led to underestimate CKD prevalence, it should not have biased the relations between eGFR level and the studied markers and outcomes. Second, data on ethnicity were not available to calculate eGFR. Because elderly people selected from these cities electoral rolls are unlikely to be of African origin, this factor should have minimal impact on eGFR estimates, but our ' reference values are only generalizable to European elderly. Third, baseline data on ACR/PCR would have been valuable to assess the independent impact on decline and mortality and to assess risk stratification using eGFR and ACR. Fourth, 26 of Bordeaux participants % alive at 4 years declined the follow-up study. They differ slightly from those included with respect to age and sex, but were highly comparable for the other baseline data including eGFR. This may have decreased study power, particularly in the subgroup analyses, but is unlikely to have systematically biased our estimates of eGFR decline. In contrast, the 137 participants who died within 4 years are likely to be those with more rapid decline, 29 and this may have underestimated the observed rate. Finally, eGFR decline rate was assessed based discrepancy. As in another community-dwelling elderly cohort, 28 eGFR declined faster in men than women, in those with than without [ ] diabetes, but no trend appeared as individual mean eGFR decreased. Although there was a trend toward steeper decline in those with poorer BP control, the association was nonsignificant in this population. The K/DOQI 3 defines decline rates higher than 4 mL/min/1.73 [ ] m per year as fast , as individuals with eGFR<60 mL/min/1.73 m might reach end-stage kidney disease within 10 years. This was found 2 " " 2 in 17 of the 3C participants. In contrast, the UK NICE defines progression as a decline >5 mL/min/1.73 m within one year or >10 % 2 mL/min/1.73 m within 5 years. 22 More than a third of 3C participants had an annual decline >2 mL/min/1.73 m , i.e., 10 in 5 years, but 2 [ ] 2 9.9 > 5 mL/min/1.73 m , which is slightly higher than the 6.8 observed in the UK East Kent population aged 70 to 80 years old. 51
Although it is well-known that mortality risk outweighs that of end-stage kidney disease, 35,36,52 this percentage may more closely [ ] assess the fraction of the elderly population with significant CKD progression to be targeted for management.
Several studies have shown that the mortality risk associated with a given eGFR level is attenuated in the elderly. 14, 34, 38, 39, 53 In [ ] younger individuals, mortality risk exceeds that of their reference category at an eGFR of 60 mL/min/1.73 m , but in those older than 75, prevalence of uncontrolled BP among those with CKD, 59 61 that of resistant hypertension has not been specifically assessed. Here, it [ -] affected 6 of those at CKD stage 3A and 16 , at stage 3B or higher. K/DOQI defined anaemia 24 is also an early and severe CKD disproportion was not seen in the 3C study with either equation, it is clear that kidney markers together with eGFR level provided a more relevant distribution for disease severity stages than previoulsy observed in the older population.
In conclusion, we have shown that the CKD-EPI equation may not improve categorization of elderly people with respect to CKD and long-term mortality risk compared with the MDRD equation. Only a fraction of those with impaired function, higher in men than women, have markers of kidney damage who might deserve specialist assessment and appropriate care. This study provides evidence that markers other than proteinuria are needed to distinguish aging kidneys from true CKD and avoid unnecessary referrals in the elderly with moderately decreased eGFR, particularly in women. 62 64 [ -] Acknowledgements:
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Figure 3
Prevalence of CKD stages and distribution of isolated low eGFR, microalbuminuria without diabetes, and at least one clinically relevant marker by CKD stage and sex Microalbuminuria defined as an albumin:creatinine ratio 3 (30) and <30 (300) mg/mmol (mg/g); clinically relevant markers include ≥ microalbuminuria with diabetes, clinical proteinuria defined as a protein:creatinine ratio 50 mg/mmol ( 500 mg/g), anaemia defined as an 
